Squarepoint
TECH icon

Squarepoint’s Bio-Techne TECH Stock Holding History

Squarepoint’s Portfolio TECH Stock Details TECH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-29,900
Closed -$2.31M – 4606
2023
Q4 		$2.31M Buy
+29,900
New +$1.97M ﹤0.01% 1902

Other funds holding TECH

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
MC
Maverick Capital Dallas, Texas $8.67B AUM 48.76% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Squarepoint's TECH Position: Q1 2026 in Review

Squarepoint reduced its Bio-Techne (TECH) stake by 93% in Q1 2026, selling an estimated $3.33M and leaving 4,159 shares worth $217K. The position accounts for ﹤0.01% of the portfolio, ranked #3916.

Squarepoint first reported a position in TECH in Q4 2017 and has held it in 29 quarters since. The position peaked at $25.4M in Q2 2025. 582 funds tracked by Wall St. Rank hold TECH as of Q1 2026.

  • Squarepoint held 4,159 shares of Bio-Techne worth $217K as of Q1 2026.
  • Squarepoint sold 55,510 Bio-Techne shares in Q1 2026, an estimated $3.33M.
  • Bio-Techne made up ﹤0.01% of Squarepoint's portfolio in Q1 2026, its #3916 holding.
  • Squarepoint first reported a position in Bio-Techne in Q4 2017 and has held it in 29 quarters since.
  • Squarepoint's Bio-Techne position peaked at $25.4M in Q2 2025.
  • 582 funds tracked by Wall St. Rank held Bio-Techne as of Q1 2026.

Based on Squarepoint's 13F filing for Q1 2026, filed 15 May 2026.